arrow
N

Norio Abiru

Nagasaki University
H指数:36
被引数:4,957

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study

伊普拉格列净抑制1型糖尿病患者钠-葡萄糖协同转运蛋白2期间胰高血糖素分泌及其与血糖控制和酮生成的关系: 多中心、开放标签、前瞻性研究的结果

2024-01-221
OA
New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version)
2024-01-079
OA
Study of Glucagon Response and Its Association with Glycemic Control and Ketogenesis after Administration of Ipragliflozin as an Adjunctive Treatment in Patients with Type 1 Diabetes (Suglat-AID)-A Multicenter, Open-Label, Prospective Exploratory Trial
2023-06-200
PRE
Comparing the clinical significance and antigen specificity of insulinoma-associated antigen-2 autoantibodies between radioimmunoassay and enzyme-linked immunosorbent assay in Japanese patients with type 1 diabetes
2022-09-304
OA
Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan: A real-world administrative database analysis

日本启动钠-葡萄糖协同转运蛋白2抑制剂的1型糖尿病患者的人口统计学和临床特征: 真实世界管理数据库分析

2022-08-012
OAAI
Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test

胰高血糖素反应对1型糖尿病患者餐后早期血糖波动的影响,而与残留的 β 细胞功能无关: 一项使用混合膳食耐受性试验的横断面研究

2021-01-2212
OAAI
RENAL FUNCTION AND PLASMA RENIN ACTIVITY AS POTENTIAL FACTORS CAUSING HYPERKALEMIA IN PATIENTS WITH THYROID CARCINOMA UNDERGOING THYROID HORMONE WITHDRAWAL FOR RADIOACTIVE IODINE THERAPY
2020-02-014
PREAI
Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy
2018-10-015
OAAI